MultiCell Soars, Gets Stem Cell Liver Patent

May 31, 2011
J. Webster
Comments Off on MultiCell Soars, Gets Stem Cell Liver Patent

Update: Now MultiCell (MCET) is over 2 cents a share, sitting at .0216 as I write this. The stock is now up over 367% today.

Never heard of MultiCell (MCET)? Neither had we, but when a stock, even a penny stock like MultiCell, screams up by over 300%, it’s worth looking into.

What’s crazy though, is this stock isn’t even worth 2 cents. Yeah, this stock sits at .0185. Crazy huh? Here are the details from Reuters:

MultiCell Technologies, Inc. announced the issuance of U.S. patent 7,935,528 by the United States Patent and Trademark Office (USPTO) relating to the isolation and use of human liver stem cells to treat liver disease. Under the terms of its license agreement with Rhode Island Hospital, MultiCell Technologies is the worldwide exclusive licensee of U.S. patent 7,935,528. The patent describes methods to isolate and use human liver stem cells to treat degenerative liver diseases, or inherited deficiencies of liver function.

What do you think? Worth taking a closer look? Tread softly with a stock like this. You’d really need some inside information to feel comfortable owning a penny stock like this or be some kind of scientist, who understands the value of a patent for liver stem cells.

Related Posts Plugin for WordPress, Blogger...

Comments are closed.